Targeting Resistance to Cancer Immunotherapy, Mondego’s Oral Drug Enters First Human Trial
MB-388 aims to improve treatment responses by acting on both tumor and immune cells. The initial study will assess safety and drug activity in healthy volunteers. Whether it can help cancer patients still requires validation in subsequent clinical trials.